4.6 Article

Diagnostic accuracy of a novel third generation esophageal capsule as a non-invasive detection method for Barrett's esophagus: A pilot study

Journal

JOURNAL OF GASTROENTEROLOGY AND HEPATOLOGY
Volume 36, Issue 5, Pages 1222-1225

Publisher

WILEY
DOI: 10.1111/jgh.15283

Keywords

Barrett's esophagus; Gastroenterology; Esophagus; Wireless; capsule imaging

Funding

  1. US Endoscopy
  2. Medtronics
  3. Fujifilms
  4. Ironwood
  5. Cosmo Pharmaceuticals
  6. Erbe

Ask authors/readers for more resources

In this pilot study, it was found that the novel esophageal capsule is not suitable for population screening of Barrett's esophagus. Further studies integrating artificial intelligence into improved quality novel esophageal capsule should be conducted for BE screening.
Background and Aim Previous two generations of esophageal capsule did not show adequate detection rates for Barrett's esophagus (BE). We assessed the diagnostic accuracy of a novel third generation capsule with an improved frame rate of 35 frames per second for the detection of BE in a pilot study. Methods This was a blinded prospective pilot study conducted at a tertiary medical center. Patients with known BE (at least C0M > 1) who presented for endoscopic surveillance (May to October 2017) were included. All patients underwent novel esophageal capsule (PillCam (TM) UGI; Medtronic) ingestion using the simplified ingestion protocol followed by standard high-definition upper endoscopy (esophagogastroduodenoscopy [EGD]). Capsule endoscopy findings were interpreted by examiners blinded to endoscopy results and compared with endoscopic findings (gold standard). Following completion of both tests, a subjective questionnaire was provided to all patients regarding their experience. Results Twenty patients (95%males, mean age 66.3 [+/- 7.9] years) with BE undergoing surveillance EGD were eligible. The mean BE length was 3.5 (+/- 2.7) cm. Novel esophageal capsule detected BE in 75% patients when images were compared with endoscopy. Novel capsule detected BE in 82% patients when the BE length was >= 2 cm. The mean esophageal transit time was 0.59 s. On a subjective questionnaire, all 20 patients reported novel capsule as being more convenient compared with EGD. Conclusions In this pilot, single-center study, novel esophageal capsule was shown to be not ready for population screening of BE. Studies integrating artificial intelligence into improved quality novel esophageal capsule should be performed for BE screening.

Authors

I am an author on this paper
Click your name to claim this paper and add it to your profile.

Reviews

Primary Rating

4.6
Not enough ratings

Secondary Ratings

Novelty
-
Significance
-
Scientific rigor
-
Rate this paper

Recommended

No Data Available
No Data Available